Etihad Cargo and supply chain company EFL (Expolanka Freight) have carried a consignment of vaccines from India to Egypt.
The temperature-sensitive shipment of 12,475,000 Tetanus and Diphtheria vaccine transited through Etihad Cargo’s Abu Dhabi hub.
The vaccine doses were produced in India, the largest vaccine manufacturing origin according to the WHO.
Maintaining the shipment integrity, requiring +2⁰C to +8⁰C temperature ranges, EFL handed over the shipment to Etihad Cargo in Mumbai, which then transitted the consignment through its hub at Abu Dhabi International Airport en route to Cairo
Martin Drew, Senior Vice President Sales and Cargo, Etihad Aviation Group, said: “This shipment underlines Etihad Cargo’s capability to transport temperature-sensitive cargo across the network and reinforces Etihad Cargo standing as an IATA CEIV Pharma-certified carrier.
“Working with partners such as EFL, Etihad Cargo leverages a collective of expertise and extensive network capabilities to provide essential logistical solutions to where they are needed most.”
Said Senthilnathan Shanmugam, Group CEO, EFL: “Supply chain resilience stems from having the right formula of partners, products and solutions, as well as a deep alignment on shared values and complimenting capabilities.
“With Etihad Cargo, we are able to deliver on our commitments and strive towards a safe and secure world for all.”
With more than three decades of experience and an extensive network across Asia, Africa, Middle East and the Americas, EFL’s specialised solutions cater to numerous industry verticals including pharmaceuticals.
It uses modern passive and active storage solutions, data tracking and real-time monitoring across the entire journey, and last-mile capabilities to overcome infrastructure and skill dependencies.
In the past year, Etihad Cargo has increased its pharmaceutical shipments by 50 per cent via its PharmaLife product. In addition to supporting global customers, the IATA CEIV-certified product has facilitated Etihad Cargo’s support of the Hope Consortium’s efforts to serve global demand for COVID-19 vaccines.
